稳健医疗业务结构均衡，消费品和医疗产品各占约 50%。2008 年起， 公司从医疗产品 ODM 出口转型为健康消费品公司，电商渠道占比超 60%，直营渠道约 30%。 2015-2024 年，公司营收复合增长率 19%，规模复合增长率 14%。2025 年上半年，公司整体盈利能力提升，净利率和毛利率均处 于周期向上阶段，预计公司将进入盈利改善周期。 公司股权结构集中，李董持股 51%。2019 年后加快引入消费品管理层， 团队架构稳定。2024 年发布股权激励计划，设定 25-27 年营收增长触 发值 13%和目标值 18%。 消费者习惯转向健康、悦己、品质便捷，内容营销平台加速渗透。公司 在棉柔巾和卫生巾领域进行创新，如添加乳霜、益生菌、全棉表层等， 并细化场景应用。 2024 年渠道结构变化，抖音增速放缓，天猫和京东提速。全棉时代等 品牌在传统渠道回暖，寻求新的增长动能。传统电商平台整体提速。 Q&A 稳健医疗 20250825 摘要 请介绍一下稳健医疗的公司背景及其主要业务结构。 稳健医疗是一家以棉为核心，涵盖医疗和消费板块协同发展的医疗健康企业。 公司的产品结构主要分为两大类：医疗产品和健康生活消费品 ...

稳健医疗 · 300888 并驾齐驱 稳健前行 2025年半年度业绩推介材料 2025 年 8 月 免责声明 19.1 21.2 26.1 26.9 Q1 Q2 营业收入 （亿元） 各季度营业收入情况 业务结构 （亿元） 医用耗材业务 消费品业务 47% 52% 其他 1% 21.1 41.8 40.6 51.6 42.7 40.3 53.0 2019H1 2020H1 2021H1 2022H1 2023H1 2024H1 2025H1 36.5% 26.7% 31.3% 本材料由稳健医疗用品股份有限公司（以下简称"公司"）准备，仅供参考和一般信息之用 。您观看本材料 就表明您已经确认并同意如下限制： 本材料中包含的信息仅供参考和一般信息之用，不得以任何方式复制 、向任何其他人披露或散发 、或在 任何其他报告或文件中引用或使用。 本材料中包含的信息为截至相应报告期日的判断，可能发生变化，公司不承担任何更新该等信息的义务。 公司或其关联人、雇员不承担任何由于对本材料或其内容的任何使用而造成的任何损失，或以其它方式产 生的与本材料相关的损失。 01 上半年财务表现 02 上半年业务回顾 上半年财务表现 两大主业 ...

[Table_Info1] [Table_Title] 证券研究报告 / 公司点评报告 消费品业务快速增长，品牌势能持续向上 --- 稳健医疗 2025 中报点评 事件： [Table_Summary] 公司发布 2025 年中报，2025H1 营业收入同比增长 31.3%至 53 亿元， 归母净利润同比增长 28.1%至 4.9 亿元。单 Q2 营业收入同比增长 26.7%至 26.9 亿元，归母净利润同比增长 20.7%至 2.4 亿元。 点评： 费用管控良好，盈利能力相对稳定。2025H1 公司毛利率同比下降 0.4pct 至 48.3%，医疗/消费品业务毛利率分别同比-0.7pct/+1.7pct 至 37.4%/58.6%。消费品业务毛利率提升主要得益于棉花价格下行及产品 结构改善。费用端，销售/管理费用率分别同比-2.5pct/+0.6pct。综合 2025H1 净利率同比下降 0.3pct 至 9.8%。 营运状况保持稳定。2025H1 公司存货同比增长 33.9%至 19.5 亿元，存 货周转天数同比下降 6 天至 142 天。应收/应付账款周转天数同比下降 1/16 天至 37/69 天。半 ...

证券代码：300888 证券简称：稳健医疗 稳健医疗用品股份有限公司投资者关系活动记录表 编号：2025-006 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （电话会议） | | 参与单位名称 | 交银施罗德基金、嘉实基金、信达澳亚基金等 139 位机构投资者，名单详见 | | 及人员姓名 | 附件（排名不分先后） | | 时间 | 年 月 日 2025 8 22 | | 地点 | 公司总部会议室 | | | 方修元：董事、首席财务官 | | 上市公司接待 | 吴克震：监事、医疗板块轮值 CEO | | 人员姓名 | 廖美珍：董事、全棉时代高级副总裁 | | | 陈惠选：副总经理、董事会秘书 | | | 介绍内容详见附件业绩推介材料，问答记录如下： | | 1. | 请问公司如何看待全棉时代近期恢复情况，并请分享一下消费品业务下 | | | 半年展望以及未来 1-2 年的核心增长动力。 | | | 答：首先，全棉时代第二季度实现 13%同比增长，公 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company, Steady Medical, within the medical supplies industry [1][2] - As of July 4, the closing price of Steady Medical was 40.2 yuan, with a decline of 2.43%, resulting in a rolling PE ratio of 30.74 times and a total market capitalization of 23.41 billion yuan [1] - The average PE ratio for the beauty and healthcare industry is 38.96 times, with a median of 43.11 times, placing Steady Medical at the 13th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, the company reported a revenue of 2.605 billion yuan, representing a year-on-year increase of 36.47%, and a net profit of 249 million yuan, also reflecting a year-on-year growth of 36.26% [2] - The sales gross margin for the company stood at 48.46% [2] - The company specializes in the research, production, and sales of cotton-based products, including high-end wound dressings and various healthcare products, and has consistently ranked among the top three exporters of medical dressings in China [1]

Company Overview - Company name is稳健医疗, which focuses on the research, production, and sales of cotton-based products [1] - Main products include high-end wound dressings, traditional wound care and bandaging products, surgical consumables, infection protection products, health personal care products, cotton towels, cotton sanitary napkins, cotton wet wipes, non-woven consumer products, baby products, and adult clothing [1] - The company has consistently ranked among the top three in China's medical dressing exports for several years [1] Financial Performance - For Q1 2025, the company reported revenue of 2.605 billion yuan, a year-on-year increase of 36.47% [2] - Net profit for the same period was 249 million yuan, also reflecting a year-on-year growth of 36.26% [2] - The sales gross margin stood at 48.46% [2] Market Position - The company's current rolling price-to-earnings (PE) ratio is 30.45, while the average PE ratio for the beauty and personal care industry is 39.12 [1][2] - The industry median PE ratio is 42.46, placing the company at 13th in the industry ranking [1] - The total market capitalization of the company is 23.188 billion yuan [1] Capital Flow - On June 26, the company experienced a net outflow of main funds amounting to 2.0955 million yuan, with a total outflow of 24.8019 million yuan over the past five days [1]

Company Overview - Company name is稳健医疗, which closed at 50.47 yuan on June 10, with a 2.25% increase, resulting in a rolling PE ratio of 38.59 times and a total market value of 29.39 billion yuan [1] - The main business of the company includes research, production, and sales of cotton-based products, with key products being high-end wound dressings, traditional wound care products, surgical consumables, infection protection products, and personal health products [1] Financial Performance - For Q1 2025, the company reported revenue of 2.605 billion yuan, a year-on-year increase of 36.47%, and a net profit of 249 million yuan, also up 36.26%, with a gross profit margin of 48.46% [2] - The company's PE ratio is 38.59 (TTM) and 42.26 (static), with a price-to-book ratio of 2.58 [2] Industry Comparison - The average PE ratio for the beauty and personal care industry is 44.04, with a median of 49.17, placing the company at 14th in the industry ranking [1][2] - The total market value of the industry averages 115.99 billion yuan, with the median at 74.78 billion yuan [2] Market Position - The company has consistently ranked among the top three exporters of medical dressings in China for several years [1] - The "winner" brand has entered over 2,000 hospitals and nearly 40,000 pharmacies in China, with a significant presence in major chains [1]

Core Insights - The article discusses the transformation of the Latin American cross-border market into a 2.0 era, emphasizing compliance and localization as key strategies for success in a rapidly changing environment [1][3]. Group 1: Market Dynamics - Latin America is experiencing a 30% growth in e-commerce, with significant regulatory changes such as Brazil's elimination of the $50 tax exemption and Mexico's 19% tax increase, leading to the exit of non-compliant sellers [1][3]. - Compliance-focused players are leveraging local warehouses and tax withholding to achieve a 50% increase in profits despite rising costs [1][5]. - Consumer demand is evolving, with beauty products seeing a 10x price premium, smart home products growing at 200%, and auto parts having a 60% repurchase rate [1]. Group 2: Product Selection - The 2.0 era necessitates data-driven product selection targeting high-margin, low-competition segments, such as health and personal care, with a focus on local consumer preferences [3]. - The use of BI tools to analyze real-time search data is crucial for identifying market opportunities and avoiding price wars [3]. Group 3: Operations and Compliance - The operational strategy must focus on compliance and leveraging social media platforms like TikTok, which has 150 million users in Latin America, to drive traffic and sales [5][6]. - TikTok's low-cost video marketing strategy can significantly enhance visibility and conversion rates compared to traditional platforms [5]. Group 4: Logistics - The logistics landscape is shifting from uncertainty to a focus on risk management and efficiency, with logistics providers needing to offer comprehensive risk control solutions [6]. - The tightening of customs policies necessitates a strategic approach to logistics, emphasizing the importance of selecting logistics partners with robust risk management capabilities [6]. Group 5: Summit Highlights - The upcoming summit will feature insights from major platforms and experts on the latest policies and data in the Latin American market, aiming to provide actionable strategies for cross-border e-commerce [9][10]. - Key topics will include product selection strategies, compliance challenges, and logistics solutions, with a focus on practical applications rather than theoretical discussions [9][10].

Core Viewpoint - The company reported a steady growth in revenue and net profit for 2024, with a significant increase in Q1 2025, indicating a positive trend in financial performance [3][4]. Financial Performance - In 2024, the company achieved a revenue of 8.98 billion yuan, a year-on-year increase of 9.7%, and a net profit attributable to shareholders of 700 million yuan, up 19.8% [3]. - For Q1 2025, the company reported a revenue of 2.61 billion yuan, representing a year-on-year growth of 36.5%, and a net profit of 250 million yuan, also up 36.3% [3]. Medical Consumables Segment - In 2024, the revenue from medical consumables accounted for 43.5% of total revenue, with a slight increase of 1.1% year-on-year. However, excluding the contribution from the acquired GRI, the revenue declined by 6.4% [4]. - The gross margin for medical consumables decreased by 3.9 percentage points to 36.5% in 2024, with a notable decline in the gross margin of infection protection products [4]. - In Q1 2025, the revenue from medical consumables surged by 46.3%, with a 10.5% growth when excluding GRI's impact [4]. Health and Lifestyle Products Segment - The health and lifestyle products segment accounted for 55.6% of total revenue in 2024, with a year-on-year growth of 17.1% and a slight decrease in gross margin by 1.0 percentage points [6]. - For Q1 2025, this segment's revenue grew by 28.8% year-on-year [6]. - Online and offline sales channels contributed to the revenue, with online sales growing by 18.9% and offline sales by 9.3% in 2024 [6][7]. Product Performance - In 2024, the revenue from infection protection products dropped significantly by 61.2%, while other product categories such as high-end wound dressings and surgical consumables showed strong growth [5]. - In Q1 2025, surgical consumables and high-end wound dressings experienced substantial growth rates of 196.8% and 21.1%, respectively [5].

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company reported strong performance in Q1, with significant contributions from both the medical and consumer goods sectors [1][13] - The revenue for 2024 reached 8.98 billion yuan, a year-on-year increase of 9.7%, while the net profit attributable to shareholders was 700 million yuan, up 19.8% [5][6] - The company has adjusted its profit forecasts for 2025 and 2026, increasing the net profit estimates by 17% and 18% respectively [13] Financial Performance - In Q1 2025, the company achieved a revenue of 2.61 billion yuan, representing a year-on-year growth of 36.5%, and a net profit of 250 million yuan, up 36.3% [6] - The medical consumables segment saw a revenue increase of 1.1% in 2024, while the consumer goods segment grew by 17.1% [7][9] - The gross profit margin for 2024 decreased by 1.7 percentage points to 47.3%, with a notable decline in the medical consumables segment [11][19] Revenue Breakdown - The medical consumables accounted for 43.5% of total revenue in 2024, with a significant contribution from the acquisition of GRI [7] - The consumer goods segment represented 55.6% of total revenue in 2024, with strong growth in online and offline sales channels [9][10] Future Projections - The company forecasts revenues of 11.17 billion yuan in 2025, with a growth rate of 24.4%, and a net profit of 1.02 billion yuan, reflecting a growth rate of 46.6% [14] - The projected EPS for 2025 is 1.75 yuan, with a P/E ratio of 30 [14][19]